Regular participation in mammography screening and state of the art treatment of breast cancer at an early phase of its development have resulted in a significant, 40–50 % decrease in breast cancer death in modern screening programs [1–6]. Clinical cancer research faces a new challenge: determining the characteristics of those breast cancers which we are still failing to manage effectively among women who attend screening regularly and receive modern therapeutic regimens. Our approach to this ch…